Clinical Report: AGA Updates HBV Reactivation Prophylaxis Guidelines
Overview
The American Gastroenterological Association has released updated guidelines for preventing hepatitis B virus reactivation in at-risk patients. Key recommendations include universal HBV testing for adults and antiviral prophylaxis for high-risk patients.
Background
Hepatitis B virus reactivation (HBVr) poses risks for patients undergoing immunosuppressive therapies. Updated guidelines provide a framework for risk stratification and prophylaxis.
Data Highlights
No numerical data provided in the source material.
Key Findings
- The panel recommends antiviral prophylaxis for high-risk patients with HBVr risk over 10%.
- Universal testing for HBsAg, anti-HBc, and anti-HBs is strongly recommended for all adults aged 18 and older.
- Moderate-risk patients should receive a conditional recommendation for prophylaxis.
- Antiviral prophylaxis reduces HBVr risk by 82% and hepatitis flare rates by 72%.
- Monitoring for low-risk patients should occur at 1-to 3-month intervals, focusing on HBV viral load and ALT levels.
Clinical Implications
Clinicians should implement universal HBV testing and consider antiviral prophylaxis for high-risk patients prior to initiating immunosuppressive therapies.
Conclusion
The updated AGA guidelines provide recommendations for the prevention and management of HBVr.
Related Resources & Content
- American Gastroenterological Association, Gastroenterology, 2025 -- AGA Updates HBV Reactivation Prophylaxis Guidelines
- The New Gastroenterologist, 2025 -- AGA Releases New Recommendations for Managing Hepatitis Delta Virus Infection
- Drug Safety, 2024 -- Guidelines for Optimal Strategies in Preventing, Identifying, and Managing Hepatitis B Virus Reactivation During Clinical Trials
- EASL Clinical Practice Guidelines on the management of hepatitis B virus infection - PubMed
- conexiant — AGA issues updated guidance on HDV management
- Journal of Gastroenterology — A Comprehensive Review of Tenofovir Alafenamide for Managing Chronic Hepatitis B Virus Infection in Asian Populations
- AGA Updates HBV Reactivation Prophylaxis Guidelines
- EASL Clinical Practice Guidelines on the management of hepatitis B virus infection - PubMed
- Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
